Background
Retrospective multicenter study evaluating low-dose total skin electron beam therapy (LD-TSEBT, 12 Gy) in combination with extracorporeal photopheresis (ECP) for erythrodermic stage T4 mycosis fungoides (MF) and Sézary syndrome (SS). Assessed response, duration of response, and toxicity of LD-TSEBT (12 Gy) compared to conventional TSEBT (≥30 Gy).
Interventions and follow up
Arm A: Low-dose TSEBT 12 Gy (typically 1 Gy × 12 fractions) ± ECP
Arm B: Conventional TSEBT ≥30 Gy; retrospective comparison or historical control
Primary endpoint: Overall response rate, response duration, toxicity
mFollow up: Not specified
Arm B: Conventional TSEBT ≥30 Gy; retrospective comparison or historical control
Primary endpoint: Overall response rate, response duration, toxicity
mFollow up: Not specified
Results
ORR (LD-TSEBT): ~75–90% (high response rates at reduced dose)
CR rate: Substantial complete skin clearance achieved in majority
Response duration: Comparable to conventional TSEBT; median FFR approximately 6–12 months
CR rate: Substantial complete skin clearance achieved in majority
Response duration: Comparable to conventional TSEBT; median FFR approximately 6–12 months
Adverse events
Toxicity: Significantly reduced compared to 30 Gy (less alopecia, nail toxicity, hypohidrosis); repeat courses feasible
Main adverse events: LD-TSEBT (12 Gy): mild-moderate skin toxicity, temporary hair thinning (not universal alopecia), less nail dystrophy than conventional dose. ECP component: fatigue, mild hypotension during procedure. Re-treatment with LD-TSEBT well tolerated.
Main adverse events: LD-TSEBT (12 Gy): mild-moderate skin toxicity, temporary hair thinning (not universal alopecia), less nail dystrophy than conventional dose. ECP component: fatigue, mild hypotension during procedure. Re-treatment with LD-TSEBT well tolerated.
Conclusions
Low-dose TSEBT (12 Gy) achieves high response rates in erythrodermic MF/SS with substantially reduced toxicity compared to conventional 30 Gy. When combined with ECP, LD-TSEBT may improve response duration. Repeat courses are feasible, making LD-TSEBT an attractive palliative strategy for this difficult-to-treat population.
Key Limitations
Key Limitations: Retrospective; heterogeneous patient population; no randomized comparison with conventional TSEBT; ECP combination makes it difficult to isolate TSEBT contribution; no standardized re-treatment protocols; selection of LD-TSEBT may reflect physician bias toward less fit patients.
Clinical Context
LD-TSEBT (12 Gy) is now widely used for erythrodermic MF and SS, especially in combination with ECP or other systemic agents. The reduced toxicity profile enables repeat courses, which is critical in this relapsing/remitting disease. ISCL/USCLC guidelines now include LD-TSEBT as an accepted option, particularly for patients who have received prior TSEBT or are not candidates for conventional dose.
References